Abaloparatide

CAS 247062-33-5

About the API

Systematic name (Amino-acid sequence) Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2
Trade name(s) Tymlos
Molecular Formula C174H300N56O49
Molecular Weight 3960.657 g/mol
Physical properties Clear
Therapeutic category Osteoporosis
Available formulations Injectables

General Information

Abaloparatide is an bone-growing (anabolic) agent indicated for the treatment of postmenopausal osteoporosis. It is intended for women at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

In clinical studies in women aged 49 to 86 years, abaloparatide significantly reduced the risk of new vertebral and nonvertebral fractures and increased bone mineral density (BMD) at the lumbar spine, total hip and femoral neck. Age had no effect on the pharmacokinetics of the drug.

It is administered as a once-daily subcutaneous injection.